Your session is about to expire
← Back to Search
Etrumadenant-Based Combinations for Colorectal Cancer (ARC-9 Trial)
ARC-9 Trial Summary
This trial will study the effects of a new drug, etrumadenant, on participants with metastatic colorectal cancer.
ARC-9 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARC-9 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARC-9 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any immune-boosting drugs in the last 4 weeks.I have active tuberculosis.I have a bleeding disorder that increases my risk of bleeding.I have never received immune checkpoint inhibitors for my condition.I have a history of lung scarring or inflammation not caused by infections.I am fully active or restricted in physically strenuous activity but can do light work.I have not taken any strong antibiotics in the last 2 weeks.I have had cancer spread to the lining of my brain or spinal cord.My blood and organs are functioning well.I have had a stem cell or organ transplant in the past.I have not had any cancer other than colorectal cancer in the last 2 years, except for non-dangerous skin cancer or a specific breast cancer.I have weak bones at risk of breaking.I have been treated with drugs targeting the adenosine pathway before.I haven't had major surgery in the last 4 weeks and don't expect to need any during the study.I have not received any live vaccines in the last 28 days.My cancer is a type of colorectal cancer that has spread.I haven't had cancer treatment in the last 4 weeks.I am currently on medication for hepatitis B.I have not had a heart attack or unstable heart conditions in the past 6 months.My cancer has a BRAF gene mutation, or I will get tested for it.You are expected to live for at least 3 more months.I cannot swallow pills.I am 18 years old or older.I agree to use birth control and not donate sperm for up to 180 days after my last treatment.My colorectal cancer worsened after one treatment including oxaliplatin or irinotecan with a biologic.My colorectal cancer worsened after up to two treatments including oxaliplatin, irinotecan, and a biologic.I have brain metastases that are untreated or getting worse.I have a condition that affects how my body absorbs pills.I have not had a severe infection in the last 4 weeks.My colorectal cancer worsened after one treatment including oxaliplatin or irinotecan and a biologic.I have or had an autoimmune disease or immune deficiency.
- Group 1: mFOLFOX-6 +/- Bevacizumab
- Group 2: Regorafenib
- Group 3: AB680 + Etrumadent+ Zimberelimab
- Group 4: Etrumadenant + Zimberelimab + mFOLFOX-6 +/- Bevacizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the capacity of participants for this medical experiment?
"Recruiting for this study has ceased; the original post was made on May 10th 2021, and it last received an update November 22nd 2022. For those seeking alternate studies, there are 873 trials actively enrolling participants with colorectal cancer and a further 870 recruiting individuals with etrumadenant."
Is this research actively seeking participants?
"As per the information on clinicaltrials.gov, this medical trial is no longer recruiting candidates. It was first published in May of 2021 and received its last edit November 22nd 2022. However, 1743 other trials are presently seeking participants for their respective studies."
In how many disparate locations is this trial occurring?
"The full list of participating hospitals includes the University of Alabama at Birmingham Comprehensive Cancer Center, Comprehensive Cancer Centers Of Nevada in Las Vegas, and Prisma Health-Upstate in Greenville. Additionally, there are 17 other locations offering this trial to patients."
Are there any past examinations of the efficacy of etrumadenant?
"Presently, there are 870 active studies on etrumadenant with 259 trials occurring in their final stage. Most of these experiments are taking place in Guangzhou, Guangdong but 38352 other locations worldwide have also joined the research effort."
In what medical situations is etrumadenant commonly prescribed?
"etrumadenant has proven to be an efficient remedy for locally advanced nonsquamous non-small cell lung cancer. Additionally, it can also treat metastatic colorectal cancer (crc), advanced gastric cancer and even some cases of immunocompromised patients."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Share this study with friends
Copy Link
Messenger